TuHURA Biosciences (HURA) Non-Current Deferred Tax Liability (2025 - 2026)
TuHURA Biosciences' (HURA) quarterly Non-Current Deferred Tax Liability came in at $197919.0 in Q1 2026, little changed quarter-over-quarter from $197919.0 in Q4 2025.
TuHURA Biosciences (HURA) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends
TuHURA Biosciences' Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $197919.0 for Q1 2026.
- On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $197919.0 in Q1 2026; TTM through Mar 2026 was $197919.0, a N/A change from a year earlier, with the FY2025 full-year figure at $197919.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability was little changed at $197919.0 in Q1 2026 per HURA's latest filing, from $197919.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $197919.0 in Q4 2025 and bottomed at $197919.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | TuHURA Biosciences | 132.62 Mn | 132.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 197,919.00 |
| Mar 31, 2026 | 197,919.00 |
| Dec 31, 2025 | 197,919.00 |
| Dec 31, 2025 | 197,919.00 |